Message from Serge Weinberg, Chairman of the Board of Directors

Dear shareholders
The third quarter of 2018, Sanofi entered a new phase of growth.
The refocusing of activities and the launch of new products enabled us to strengthen our positions, in particular in Vaccines, Rare Diseases, Multiple Sclerosis, Immunology as well as Consumer Healthcare, and to build new franchises such as Rare Blood Disorders. This step was essential to adapt Sanofi to a fast-evolving environment and also to compensate for the losses of exclusivity, particularly in Diabete...

Interview with Olivier Brandicourt, CEO

Third quarter 2018 results mark the return to growth that you announced. What were the highlights?
As a result of our strong performance in the third quarter, we are now well positioned to deliver growth...
Could you tell us more about these new products?
The third quarter was full of good news for our Specialty Care business...
You have announced a new organization of your

global business units in 2019. What are the expected changes?
We want to further refocus our activities in mature markets and across emerging markets...

Third quarter 2018 results

Third-quarter sales growth led by Specialty Care and Vaccines
Specialty Care franchise (Sanofi Genzyme) sales were up +34.6% (+16.4% at CER/CS) driven by the Immunology and Rare Blood Disorders franchises. Vaccines delivered solid growth with sales up +8.2%, supported by the Polio/Pertussis/Hib vaccines
Strong contribution from Emerging Markets
Sales: €2,529M, +10.4%


Dupixent® in asthma

Dupixent® approved for treatment of moderate-to-severe asthma patients in the United States.
The U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab) as an add-on maintenance therapy for two important groups of uncontrolled asthma patients: those who are moderate-to-severe with an eosinophilic phenotype – an inflammatory subtype frequent in severe asthma – or those with oral corticosteroid dependent asthma.

More news on Dupixent®

  • Positive phase 3 results in adolescent with moderate-to-severe atopic dermatitis
  • Positive phase 3 topline results in patients with chronic rhinosinusitis with nasal polyps
  • Read the news
  • All Sanofi news

R&D achievements and partnerships

  • Libtayo® approved in the United States for a type of skin cancer
  • Praluent® evaluated as potential treatment to reduce major adverse cardiovascular events
  • Approval of Dengvaxia® recommended in Europe
  • Partnership in neurological and inflammatory diseases
  • Read the article


Global Business Units: a more focused organization to sustain a new growth phase

Sanofi will change the organizational structure of two of its Global Business Units (GBU) to strengthen its relationship with healthcare professionals and all other stakeholders in mature markets and across emerging markets.
Discover the new organization to be implemented beginning of 2019, with the launch of the two new GBUs: Primary Care and China & Emerging Markets.

China: Sanofi’s second largest market

After 36 years on the Chinese market, with great performance achieved over the past years, China has become our second largest market worldwide. The creation of a new GBU exclusively focused on China & Emerging Markets should allow us to better capture future growth opportunities and address challenges ahead.

Shareholder information

Salon Actionaria 2018

The Salon Actionaria 2018, Europe's largest exhibition for individual shareholders, was held on November 22 and 23, 2018 in Paris.
The Investor Relations team was on-site to meet current and potential individual shareholders and answer their questions.

Share performance in Paris

On November 16, 2018, Sanofi had a market capitalization of more than €99bn.

Discover here the Sanofi upcoming shareholder and investor events


Contact the Individual Shareholder Relations team

54 rue La Boétie
75008 Paris FRANCE

France +33 800 075 876 •

United States +1 888 516 3002